Saudi Heart Association Position Statement on Troponin Use for Cardiovascular Risk Screening in Asymptomatic Populations
Journal of the Saudi Heart Association · 05.08.2025 · 37 (3)
DOI: 10.37616/2212-5043.1444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Saudi Heart Association, online erschienen am 05.08.2025. Verfasst von Waleed AlHabeeb und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Cardiovascular disease (CVD) remains the leading cause of death and disability globally. In Saudi Arabia, the burden of CVD is exceptionally high, with age-standardized mortality and prevalence rates that far exceed global averages. The current CVD risk prediction tools have several limitations, and those classified as low to intermediate risk still experience cardiovascular events, underscoring the urgent need to address CVD through effective screening and prevention strategies.
Methods
A panel of Saudi experts reviewed evidence on the use of high-sensitivity cardiac troponin (hs-cTn) to enhance cardiovascular risk assessment among seemingly healthy individuals. Consensus recommendations tailored to the Saudi context were formulated based on the literature and local clinical practice, taking into consideration the characteristics of the Saudi population, local healthcare system, available resources and medical expertise. Results and conclusions: Cardiac troponins are biomarkers of myocardial injury that can be detected in most seemingly healthy individuals using high-sensitivity assays. Studies have shown that measuring hs-cTn is a reliable predictor of future cardiovascular events in the general population. Consequently, incorporating hs-cTn into cardiovascular risk assessments could significantly improve the accuracy and effectiveness of existing risk stratification models. The experts highlighted the additional benefits of this approach compared to current risk assessment methods. This document aims to guide the integration of hs-cTn into cardiovascular risk assessment and prevention strategies for seemingly healthy individuals.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia.
- Department of Adult Cardiology, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.
- Department of Adult Cardiology, King Saud bin Abdulaziz University for Health Sciences, COM-WR, Jeddah, Saudi Arabia.
- Department of Adult Cardiology, King Abdullah International Research Center, Jeddah, Saudi Arabia.
- Department of Cardiovascular Prevention Unit, Prince Sultan Cardiac Centre, Riyadh, Saudi Arabia.
- Department of Adult Cardiology, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia.
Zitieren
APA
AlHabeeb, W., Kinsara, A. J., Alnouri, F., Alamri, H., Alshammeri, O., Albacker, T., Al Faraidy, K., AlKashkari, W., AlSaif, S., Balghith, M., & Borai, A. A. (2025). Saudi Heart Association Position Statement on Troponin Use for Cardiovascular Risk Screening in Asymptomatic Populations. Journal of the Saudi Heart Association, 37(3). https://doi.org/10.37616/2212-5043.1444
Vancouver
AlHabeeb W, Kinsara AJ, Alnouri F, Alamri H, Alshammeri O, Albacker T, et al. Saudi Heart Association Position Statement on Troponin Use for Cardiovascular Risk Screening in Asymptomatic Populations. Journal of the Saudi Heart Association. 2025;37(3). doi:10.37616/2212-5043.1444
BibTeX
@article{AlHabeeb2025,
author = {AlHabeeb, Waleed and Kinsara, Abdulhalim J and Alnouri, Fahad and Alamri, Hussein and Alshammeri, Owayed and Albacker, Turki and Al Faraidy, Khalid and AlKashkari, Wail and AlSaif, Shukri and Balghith, Mohammed and Borai, Anwar A},
title = {Saudi Heart Association Position Statement on Troponin Use for Cardiovascular Risk Screening in Asymptomatic Populations},
journal = {Journal of the Saudi Heart Association},
year = {2025},
volume = {37},
number = {3},
doi = {10.37616/2212-5043.1444}
}
EUVIMED